Accueil   Agenda - News   Toutes les news Vetbiobank obtained an authorization for manufacturing veterinary cell-based therapy

Vetbiobank obtained an authorization for manufacturing veterinary cell-based therapy

Vetbiobank confirms its leading position in veterinary regenerative medicine by obtaining for its new facility the first authorization issued in France for manufacturing veterinary cell-based therapy.

 

Since 2011 Vetbiobank has brought to light the potential of neonatal mesenchymal stem cells to successfully treat animal chronic inflammatory diseases.


In just a few years, we have been able to demonstrate to:
- The scientific and veterinary community, the remarkable long-term efficacy of our neonatal stem cells for chronic inflammatory conditions (Cabon et al, Frontiers Vet Science 2019; Taroni et al, Frontiers Vet Sci. 2017).
- Horse and dog’s owners that our products are produced through an ethical process using stem cells collected at birth, therefore respecting completely animal welfare (i.e. without medical or surgical intervention impacted on the donor).
- Industrial partners, the business potential of our product, with an initial contract renewed in May 2019 for the development of canine osteoarthritis treatment.
- Investors the management’s ability to deliver value, and in return they showed their faith during the company’s 2019 financial round, by contributing more than one million euros.

 

Lire le communiqué de presse

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte